Protara Therapeutics, Inc. 8K

Protara Therapeutics announced second quarter 2026 results and pipeline updates, including key timelines for TARA-002 and IV Choline Chloride trials and an expected BLA filing for TARA-002 in lymphatic malformations in 2H 2027, supported by a cash runway into 2028.

On August 11, 2026, Protara Therapeutics, Inc. reported its unaudited financial results for the quarter ended June 30, 2026 and provided a business update, highlighting continued advancement of its lead candidate TARA-002 in non-muscle invasive bladder cancer and lymphatic malformations, including plans to complete enrollment of the BCG-unresponsive cohort of the registrational ADVANCED-2 trial and redesign the ADVANCED-3 trial as a broader exploratory NMIBC study, as well as progress in the pivotal STARBORN-1 LM trial with an expected BLA submission in the second half of 2027 and ongoing THRIVE-3 Phase 3 trial of IV Choline Chloride with interim data anticipated in the fourth quarter of 2026; the company also disclosed a net loss of $21.7 million for the quarter, research and development and general and administrative expense increases, and a cash, cash equivalents and investments balance of approximately $162 million expected to fund operations into 2028.

Filing Facts

CIK

1359931

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-087506

Alert Tier

6